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Abstract
Background: Colorectal cancer (CRC) appear to arise from precursor lesions in a well-characterized adenoma-
carcinoma sequence. Significant efforts have been invested to develop biomarkers that identify early
adenocarcinomas and adenomas with high-grade dysplasia, since these are believed to harbor a particularly high
risk for malignant transition and thus require resection. Promoter methylation of SEPT9 and SHOX2 has been
suggested as a biomarker for various solid malignant tumors. Hence, the present study aimed to test their biomarker
potential in CRC and precursor lesions.
Results: Assessment of promoter methylation of SEPT9 distinguished adenomas and CRC from controls as well as
advanced from non-advanced adenomas (all p < 0.001). Correspondingly, SHOX2 methylation levels in adenomas and
colorectal carcinomas were significantly higher compared to those in normal control tissues (p < 0.001). Histologic
transition from adenomas to CRC was paralleled by amplification of the SEPT9 gene locus.
Conclusions: SEPT9/SHOX2 methylation assays may help to distinguish colorectal cancer and adenomas from normal
and inflammatory colonic tissue, as well as advanced from non-advanced adenomas. Further studies need to validate
these findings before introduction in clinical routine.
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Background
Colorectal cancer (CRC) is one of the most common
and intensively studied cancer entities worldwide [1]. Al-
though its molecular pattern is to a certain extent het-
erogeneous, more than 80 % of sporadic CRC appear to
arise from precursor lesions [2]. The “adenoma-carcin-
oma sequence” [3] reflects this transition with a genetic
characteristic, e.g., mutations in TP53, KRAS, and APC,
[4] and histopathologic alterations [5, 6]. The evolving
knowledge about precancerous lesions of CRC, the
oftentimes slow progression towards malignant trans-
formation, and a tremendously better prognosis for early
detected and treated CRCs make this cancer entity par-
ticularly attractive for screening strategies [7]. Owing to
multimodal therapy regimes, improved surgical tech-
niques, and screening programs, incidence of CRC has
steadily decreased over the last decades [8, 9]. Despite
this significant success, population’s enrollment in rec-
ommended screening programs is difficult [10] and sig-
nificant efforts have been invested in the development of
non-invasive diagnostic tests. Nonetheless, colonoscopy
remains the non-replaceable gold standard in every CRC
screening program [11, 12].
Epigenetic changes to genomic tumor DNA are bio-
stable and often cancer-specific alterations that are
therefore issue of numerous ongoing research projects
worldwide [13]. Our and other groups established differ-
ential methylation-specific qPCR assays of the stature
homeobox 2 (SHOX2) and septin 9 (SEPT9) in various
cancer entities with possible biomarker properties for
early detection and response prediction strategies [14].
For example, our team previously used a combined assay
* Correspondence: papers.semaan@gmail.com
†Equal contributors
1Department of General, Visceral, Thoracic and Vascular Surgery, University of
Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Semaan et al. Clinical Epigenetics  (2016) 8:100 
DOI 10.1186/s13148-016-0267-5
to measure SHOX2 and SEPT9 promoter methylation
for the discrimination between benign and malignant
pleural effusions [15]. Promoter methylation of SEPT9, a
gene encoding for a GTP-binding protein with various
functions in formation and control of the cytoskeleton,
proved to be present in >90 % of CRC specimens (mean
methylation level 26 %, range 0–89 %) [16–18]. Further-
more, SEPT9 DNA methylation in blood plasma was suc-
cessfully validated in a large prospective trial including
~8000 asymptomatic subjects, undergoing routine colon-
oscopy (ClinicalTrials.gov Identifier: NCT00855348) [19].
Consequently, SEPT9-based diagnostic tests for colorectal
cancer screening are available to patients in Europe and
the USA as CE-marked In Vitro Diagnostics (CE-IVDs)
and Laboratory Developed Tests (LDTs). Very recently,
the American Food and Drug Administration (FDA) ap-
proved the commercial SEPT9 methylation assay, “Epi
proColon®,” as a blood-based in vitro diagnostic (IVD) test
for screening of CRC. However, the SEPT9 methylation
pattern of adenomas has only been studied in a small
amount of studies [20–24]. It is known today that certain
types of adenomas harbor an increased risk for malignant
transformation [25] and that adenomatous subtypes carry
different epigenetic profiles [26]. Up-to-date detailed in-
formation about the SEPT9 methylation status in different
types of adenomatous polyps is still fragmentary.
SHOX2 harbors two large CpG islands, located at the
3′ and the 5′ end of the gene, and is involved in limb
formation and cardiac development [27, 28]. So far, the
SHOX2 DNA methylation status has mainly been evalu-
ated for its value in the detection of lung cancer with
reasonable success [29–34]. More than 90 % of histolog-
ically confirmed lung cancer patients showed a hyperme-
thylation of this gene locus in comparison to normal
tissue [35]. Additionally, the SHOX2 methylation status
showed promising results in other cancer types [15, 36].
In order to probe the apparently broad utility of SHOX2
as a biomarker in CRC, this target was included in the
present study.
Results
Stepwise increase of SEPT9 methylation from non-cancerous
to cancerous tissue
In the Triplex assay, SEPT9 promoter methylation levels
showed a gradual increase from the control group
(4.4 % ± 9.9), over non-advanced (N-AA, 72.7 % ± 63.3)
and advanced adenomas (AA, 150.2 % ± 110.05), to CRC
(294.8 % ± 219.2, Fig. 1a). The Triplex SEPT9 methyla-
tion assay was able to differentiate between CRCs vs.
controls (p < 0.001), CRCs vs. adenomas (p = 0.001) and
CRC vs. AA (p < 0.001), CRC vs. N-AA (p < 0.001). Add-
itionally, AA showed a hypermethylation compared to
N-AA (p < 0.001) or control (p < 0.001).
Receiver operating characteristic (ROC) analyses showed
that SEPT9 hypermethylation was able to distinguish be-
tween CRC vs. control (AUC= 0.96, 95 % CI = 0.90–1.00,
p < 0.001) and adenomas vs. control (AUC = 0.97, 95 % CI
= 0.93–1.00, both p < 0.001; Fig. 2a, b).
In total, 59/166 (35 %) specimens showed a SEPT9
methylation level ≥100 % (highest methylation level of
789 %) and again a stepwise increment was noted from
control to CRC. In the CRC group, 19/25 (76 %) showed
a methylation level ≥100 %, whereas 39/75 (52 %) aden-
omas and 0/62 controls had a methylation level ≥100 %.
The QM assay also showed an increase in the SEPT9
methylation level from the control group (2.4 % ± 3.2),
over adenomas (55.8 % ± 29.3), to CRC (60.9 % ±26.9).
N-AA (36.7 ± 26.6 and AA 67.5 ± 24.6) also showed an
increase in the SEPT9 methylation level (p < 0.001,
Fig. 1b). Although the QM assay showed different
methylation levels between CRC vs. controls (p < 0.001),
CRC vs. N-AA (p = 0.002), and AA vs. controls (p <
0.001), this assay was not able to differentiate between
CRC vs. AA (p = 0.29) and CRC vs. adenomas (p = 0.43).
a) b)
Fig. 1 SEPT9 methylation quantified with Triplex and QM assays, respectively, comparing the different subgroups (control vs. non-advanced vs.
advanced adenomas vs. CRC). Comparison of different SEPT9 methylation levels obtained from the a Triplex assay (control n = 62, N-AA n = 24, AA
n = 48, CRC n = 25) and b QM assay (control n = 63, N-AA n = 24, AA n = 48, CRC n = 28). **p < 0.001 marks significant differences in methylation
levels between the indicated subgroups, and *p < 0.05 marks significant differences in methylation levels between the indicated subgroups. N-AA
non-advanced adenomas, AA advanced adenomas
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ROC analyses showed that SEPT9 hypermethylation
was able to distinguish between CRC vs. control (AUC=
0.95, 95 % CI = 0.88–1.00, p < 0.001) and adenomas vs.
control (QM: AUC= 0.96, 95 % CI = 0.93–0.99, p < 0.001;
Fig. 2a, b).
SHOX2 methylation shows a gradual increase from
non-cancerous tissues to CRC
As shown for the SEPT9 gene locus, SHOX2 showed a
gradual step-up in the methylation level from control
(1.3 % ± 1.5), over N-AA (26.3 % ± 29.6) and AA (46.7 % ±
44.9), to CRC (65.7 % ± 35.4), in the Triplex assay. Aden-
omas showed a SHOX2 methylation level of 40.2 % ± 40.6
without separation in N-AA and AA. SHOX2 methylation
level was able to discriminate CRC vs. control (p < 0.001),
CRC vs. N-AA (p = 0.01), N-AA vs. AA (p = 0.025), AA vs.
control (p < 0.001), and N-AA vs. control (p < 0.001).
Nonetheless, this assay was not able to distinguish
between CRC vs. AA (p = 0.44) and CRC vs. adenoma
(p = 0.12, Fig. 3).
Fig. 2 ROC curves for SEPT9 and SHOX2 methylation (determined via QM and Triplex assays) in the different subgroups. a SEPT9 CRC vs. control.
b SEPT9 adenoma vs. control. c SHOX2 CRC vs. control. d SHOX2 adenoma vs. control
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ROC analyses showed that SHOX2 hypermethylation
was able to discriminate between CRC vs. controls
(AUC = 0.91, 95 % CI = 0.81–1.00, p < 0.001) and aden-
omas vs. controls (AUC = 0.88, 95 % CI = 0.82–0.94, p <
0.001, Fig. 2c, d). However, SHOX2 methylation assay
failed in the differentiation between CRC and adenoma
(AUC = 0.60, 95 % CI = 0.48–0.74, p = 0.095).
In total, 11/166 (7 %) specimens showed a SHOX2
methylation level in the Triplex assay ≥100 % (highest
methylation level of 179 %). There was no difference be-
tween the groups with 3/27 (11 %) in the CRC group, 8/
75 (11 %) in the adenoma group, and 0/63 in the control
group.
The QM assay also showed an increase of the SHOX2
methylation level from controls (1.5 % ± 2.3), over N-AA
(44.3 % ± 36.3) and AA (59.5 % ± 37.2), to CRC (65.7 %
± 35.4). Adenomas showed a SHOX2 methylation level
of 55.3 % ± 36.9 without separation in N-AA and AA.
SHOX2 methylation level was able to discriminate CRC
vs. control (p < 0.001), CRC vs. N-AA (p = 0.036), AA vs.
control (p < 0.001), and N-AA vs. control (p < 0.001).
Nonetheless, this assay was not able to separate CRC
from N-AA, AA, or adenomas (all p > 0.05) or AA from
N-AA (p > 0.05, Fig. 3).
ROC analyses showed that SHOX2 hypermethylation
was able to discriminate between CRC vs. controls
(AUC = 0.88, 95 % CI = 0.77–0.99, p < 0.001) and aden-
omas vs. controls (AUC = 0.90, 95 % CI = 0.85–0.95, p <
0.001, Fig. 2c, d). However, SHOX2 methylation assay
failed in the differentiation between CRC and adenoma
(AUC = 0.56, 95 % CI = 0.43–0.69, p = 0.33).
SEPT9 and SHOX2 methylation status in advanced
adenomas
For three patients with colorectal adenoma, no informa-
tion regarding size and grade of dysplasia could be re-
trieved, narrowing the amount of individuals in this
analysis to 72.
In correlation to the stepwise increase of SEPT9 and
SHOX2 methylation level, the adenoma group was evalu-
ated for other characteristics with known potential for
supporting a malignant transition.
In the Triplex assay, size ≥10 mm was significantly
correlated with the methylation level of SEPT9 (ρ = 0.40,
p < 0.001), but showed no difference in the methylation
level of SHOX2 (ρ = 0.21, p = 0.083). Interestingly, those
adenomas larger than ≥10 mm in size (n = 48) showed
more frequently SEPT9 methylation levels ≥100 % than
adenomas ≤10 mm (n = 24) (33/48 (68 %) vs. 6/24
(25 %), p < 0.001). No difference between small and large
adenomas was found regarding SHOX2 methylation
levels ≥100 % (p = 0.19). Correspondingly, the highest
grade of epithelial dysplasia (D1-3) [37] is correlated
with significantly higher methylation of SEPT9 (ρ = 0.24,
p = 0.047), but not of SHOX2 (ρ = −0.06, p = 0.58).
In the QM methylation assay, size ≥10 mm was corre-
lated with the methylation level of SEPT9 (ρ = 0.48, p <
0.001) and SHOX2 (ρ = 0.24, p = 0.047). The highest
grade of epithelial dysplasia (D1-3) [37] showed a trend
of higher methylation of SEPT9 (ρ = 0.23, p = 0.056), but
not of SHOX2 (ρ = −0.06, p = 0.60). Adenomas with a
size ≥10 mm had a higher SEPT9 methylation level (67.5
vs. 36.7 %, p < 0.001) compared to small adenomas, but
no difference was found in SHOX2 (59.5 vs. 44.3 %, p =
0.10).
SEPT9 and SHOX2 methylation levels in adenoma subtypes
Regarding the methylation status of the SEPT9 gene
locus, (tubulo-)villous adenomas showed the highest
methylation levels of all adenomas, irrespective of assay
type. Consequently, villous adenomas showed a signifi-
cant hypermethylation of SEPT9 (Triplex assay) in com-
parison to serrated adenomas (164.9 vs. 70.3 %, p =
0.022, Fig. 4). All other types of adenomas showed no
difference in methylation using the Triplex assay. Ac-
cording to results from the Triplex assay, QM assay
a) b)
Fig. 3 SHOX2 methylation quantified with Triplex and QM assays, respectively, comparing the different subgroups (control vs. adenomas vs. CRC).
Comparison of different SHOX2 methylation levels obtained from the a Triplex assay (control n = 62, adenomas n = 75, CRC n = 25) and the b QM
assay (control n = 63, adenomas n = 75, CRC n = 28) for the three subgroups. **p < 0.001 marks significant differences in methylation levels between
the indicated subgroups, and *p < 0.05 marks significant differences in methylation levels between the indicated subgroups
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analysis also showed a significant hypomethylation of
serrated adenomas compared to villous adenomas (QM
34.2 vs. 63.7 %, p = 0.003; Triplex 70.3 vs. 164.9 %, p =
0.022) and tubulovillous adenomas (QM 34.2 vs. 74.2 %,
p < 0.001; Triplex 70.3 vs. 152.0 %, p = 0.051). Addition-
ally, tubulovillous in comparison to tubular adenomas
showed a different SEPT9 methylation level (QM 74.2
vs. 49.8 %, p = 0.029) (Fig. 4).
In contrast to SEPT9, methylation levels of the SHOX2
gene locus revealed no difference between the various
types of adenomas in both methylation assays (QM: vil-
lous vs. tubulovillous, villous vs. serrated, and villous vs.
tubular, all p > 0.5; tubulovillous vs. tubular, p = 0.26 and
serrated vs. tubular, p = 0.082) (Triplex: villous vs. tubu-
lovillous, villous vs. serrated, villous vs. tubular, and ser-
rated vs. tubular, all p > 0.5; tubulovillous vs. tubular, p =
0.20) (Fig. 5).
Microsatellite instability
No correlation between any type of microsatellite in-
stability (MSI) (MLH1, PMS2, MSH2, and MSH6),
amplification of SEPT9 and SHOX2, and clinical parame-
ters were found (all p > 0.5).
Discussion
Large screening programs have decreased the incidence
of CRC [8, 9], but low compliance rates especially re-
garding preventive colonoscopy hamper a maximum
success of modern primary prevention strategies [11].
The principle of “tailored screening” may improve
screening effectiveness by stratification into risk tiers
[38]. Therefore, entirely non-invasive early detection
tests for CRC are urgently needed.
Epigenetic alternations of the SEPT9 gene locus were
previously described in minor series of tissue from colo-
rectal adenomas [20–23] or blood samples [24, 39]. The
presented comprehensive data confirmed previous find-
ings and highlight the relevance of SEPT9 methylation
in these lesions. Moreover, it was revealed that the as-
sessment of promoter methylation of SEPT9 as well as
SHOX2 may actually help distinguish CRC and aden-
omas from normal epithelium without dysplasia. These
results are in line with Tänzer et al. who found a higher
Fig. 4 SEPT9 methylation quantified with QM and Triplex assays, respectively, comparing different adenoma subtypes. Comparison of different
SEPT9 methylation levels in the a Triplex and b QM assays for the four adenomatous subgroups (tubular n = 16, tubulovillous n = 21, villous
n = 18, serrated n = 20). **p < 0.001 marks significant differences in methylation levels between the indicated subgroups, and *p < 0.05 marks
significant differences in methylation levels between the indicated subgroups
Fig. 5 SHOX2 methylation quantified with QM and Triplex assays, respectively, comparing different adenoma subtypes. Comparison of different
SHOX2 methylation levels obtained from the a Triplex and b QM assays for the four adenomatous subgroups (tubular n = 16, tubulovillous n = 21,
villous n = 18, serrated n = 20). No significance level p < 0.05 has been reached in these assays
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frequency of SEPT9 and ALX4 DNA methylations in
plasma of AA compared to healthy controls [23]. On top
of that, the methylation status of SEPT9 as quantified
with our Triplex assay was able to distinguish between
adenomas vs. CRC and AA vs. N-AA. Despite their stat-
istical significance, the methylation level of both genes
within the subgroup showed a scattered and partly over-
lapping distribution, elevating the risk of false positive or
negative results. These observations are in line with the
finding that epigenetic changes resemble an early event
in the carcinogenesis of CRC [40, 41]. In accordance,
genome-wide comprehensive methylation analysis of ad-
enomas and CRC tissue revealed accumulation of
epigenetic alternations in the progression from early ad-
enomas towards invasive adenocarcinomas [42, 43]. Al-
though, advanced adenomas are believed to harbor an
increased potential for malignant transformation (see
[44] and [25]), a direct proof of malignant transform-
ation of advanced adenomas or of a certain histologic
subtype remains somewhat elusive.
Interestingly, a stepwise increase of the SEPT9 methy-
lation level from controls over not-advanced adenomas
to advanced adenomas and invasive adenocarcinoma
could be observed. This may explain false positive test
results of the Epi proColon® test indicating methylated
DNA segments in the SEPT9 region in the absence of an
invasive CRC. SEPT9 may therefore potentially be used
as an ancillary marker in the identification of advanced
adenomas in case of difficulties with histologic diagnosis
of a colorectal biopsy (i.e., due to cautery artifacts). Add-
itionally, the presented data support a future inclusion
of SEPT9 and SHOX2 in methylation biomarker panels
to support the diagnosis of CRC, though both markers
have to be validated in a large prospective trial. By com-
bining these and other markers, overlapping results es-
pecially between AA and CRC may be minimized.
Surprisingly, >50 % of SEPT9 Triplex methylation
levels in CRC and adenomas showed a value exceeding
100 %, technically reasoned by a distant location of the
reference gene (ACTB at chromosome 7) and the ana-
lyzed gene loci (SEPT9 gene at chromosome 17 and
SHOX2 at chromosome 3q) [15]. Hence, higher methyla-
tion values in comparison to QM assay may be due to
focal amplification of the SEPT9 gene locus and/or a de-
letion of the reference gene (ACTB). A SEPT9 amplifica-
tion later during carcinogenesis is supported by the
observation that especially advanced adenomas and car-
cinomas showed a level >100 % in the Triplex assay.
These findings are in congruence with the results from
Ben-David et al. who found that genes, which have been
up-regulated in early adenomas, showed a tendency for
amplification in later stages of colorectal carcinogenesis
[45]. Taken together, one may carefully speculate that
promoter hypermethylation of SEPT9 triggers a focal
amplification that may foster a malignant transition from
adenoma to invasive carcinoma. This mirrors the as-
sumption of Saha et al. and Bardelli et al. that gene amp-
lification is attributed to play a role in stage transition of
CRC [46, 47]. Concordantly, SEPT9 amplification has
only been identified in advanced breast cancer patients
[48] and in vitro [49], while early localized tumors
showed no SEPT9 amplification. Additionally, the same
group was able to identify a worse survival in endomet-
rial adenocarcinoma, which shows a copy number
variation (CNV) of SEPT9 [50]. In contrast to this hy-
pothesis, SEPT9 amplification was only found in 0.4 % of
CRC in a cohort of 257 CRC patients and in 2/615 CRC
cases of the TCGA data repository (0.3 %) [4]. If the
above assumptions are proven true, SEPT9 may be an
excellent plasmatic biomarker. Because, due to DNA
amplification, the total number of tumor DNA alleles in
plasma including their specific epigenetic SEPT9 alter-
ation may be easier to detect among background DNA.
This phenomenon has already been evidenced for
SHOX2 in squamous cell lung cancer [34]. Another pos-
sible explanation for this phenomenon was hypothesized
to be a MSI, which is known for causing hyper-mutated
and epigenetically altered genomes [4]. However, no cor-
relation between MSI and amplifications of SEPT9 and
SHOX2 or clinical parameters were found in the present
study.
Overall, SEPT9 methylation showed a better perform-
ance than SHOX2 in distinguishing the different study
groups. This finding is in line with results about the po-
tential of plasmatic free-circulating tumor DNA and
tissue SEPT9 methylation [17–19, 51–53], although
sensitivity (52–94 %) and specificity (88–95 %) vary
greatly between the studies [17, 18, 51, 54]. This vari-
ability may be attributed to different testing methods or
common pre-existing conditions like high age, gender,
and comorbidities and have to be interpreted with cau-
tion [53, 55].
The present study has several limitations. For example,
only a small series was included and analyzed in a retro-
spective fashion hampering statistical power and lower-
ing the evidence level. Furthermore, methylation assays
have only a limited suitability to detect CNV, and more
sensitive assays (e.g., FISH, CGH, or next-generation se-
quencing) have to validate the data.
Conclusions
In conclusion, SEPT9 or SHOX2 methylation may be
auxiliary biomarkers for the differentiation of CRC and
advanced adenomas to non-advanced adenomas and
normal tissue. Ideally, both markers should be integrated
into a marker panel for CRC screening and validated in
a large prospective trial. The investigations suggest that
CNV of SEPT9 may contribute to a malignant transition
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from adenomas into advanced adenomas and adenocar-
cinomas. Further studies with CNV sensible assays are
needed to elucidate the distinct role of these gene loci in




The study was approved by the Institutional Review
Board (IRB) of the University Hospital of Bonn (Num-
ber: 222/13). Formalin-fixed, paraffin-embedded (FFPE)
tissue specimens from 166 patients, treated or diagnosed
at the University Hospital of Bonn academic hospitals
between 2002 and 2013, were included. The study group
included various non-invasive epithelial lesions including
tubular adenomas, tubulovillous adenomas, villous aden-
omas, and serrated adenomas. Furthermore, sporadic
colorectal cancer were included. Patients with a history
of familial adenomatous polyposis (FAP), Lynch syn-
drome, or other second primary malignancy were not
included. Additionally, patients with Crohn’s disease
showing high-grade dysplasia in the resected specimen
or in any biopsy taken at time of admission were ex-
cluded from the study. All specimens were histologically
diagnosed by an experienced pathologist blinded to the
patient’s history. Histologic classification was performed
according to the most recent recommendations by the
World Health Organization [56] and the latest TNM
classification [57]. Advanced adenomas were defined as
adenomatous polyps with a size ≥10 mm, ≥25 % of vil-
lous features, or a high-grade dysplasia [58–61].
Patient characteristics
The study cohort comprised tissue specimens from 166
patients (102 ♂, 64 ♀) with a mean age of 67 years
(range 38–91). Age and gender were distributed equally
in the following groups (all p > 0.5). The CRC group em-
bodied 28 patients (18 ♂, 10 ♀) with a mean age of
69 years (range 42–90). This group included 7 stage I, 7
stage IIa, 3 stage IIb, 3 stage IIIa, 1 stage IIIb, 4 stage
IIIc, and 3 stage IV CRCs. The adenoma group con-
tained 75 individuals (45 ♂, 30 ♀) with a mean age of
68 years (range 38–89). Sixteen of the adenomas were
described as tubular, 21 as tubulovillous, 18 as villous,
and 20 as serrated adenomas. Twenty-four of 75 aden-
omas (32 %) measured <1 cm, and 48/75 (64 %) had a
size >1 cm, while 3 datasets were missing (4 %). The
mean size of adenomas was 2 cm, the median 1.5 cm
(range 0.3–8 cm). Fifty-three adenomas of 75 (70.7 %)
showed a low or moderate grade of dysplasia, 19/75
(25.3 %) showed high-grade dysplasia, while 3 datasets
were missing (4 %). The control group comprised of 63
patients (39 ♂, 24 ♀) with a mean age of 66 years (range
39–91). This group contained 34 normal adjunct tissue
specimens (NAT), 23 specimens diagnosed with Crohn’s
disease and admitted for surgical colon resection be-
cause of obstruction, abscesses, or fistula and 6 speci-
mens with colonic diverticulosis.
Valid Triplex assay measurements were obtained from
25 CRCs; 75 adenomas, including 16 tubular, 21 tubulo-
villous, 18 villous, and 20 serrated adenomas; and 62
controls.
Valid QM assay measurements were obtained from 28
CRC, 75 adenoma (16 tubular, 21 tubulovillous, 18 villous,
and 20 serrated adenomas), and 63 control specimens.
TCGA data
Data plots for CNV were conducted using cBioPortal
(http://www.cbioportal.org/index.do) [62, 63] and the
gene-centric GISTIC analyses provided at http://www.
broadinstitute.org/tcga/home [64]. These results are in
whole based upon data generated by the TCGA Research
Network (http://cancergenome.nih.gov/).
DNA extraction and methylation analysis
DNA extraction was performed using the Bisulfite All-
In-One Kit (innuCONVERT, Analytik Jena, Germany).
The detailed protocol is described elsewhere [65, 66].
Locus-specific analyses of DNA methylation patterns
were performed using two different PCR methods of
methylation analyses for each specimen: (1) Triplex
methylation-specific qPCR (Triplex qMSP) [15] and (2)
quantitative methylation PCR (QM PCR) [67].
SHOX2/SEPT9/ACTB Triplex assay
As previously described, a methylation-specific Triplex
qPCR assay was used [15]. It quantifies the number of
methylated SHOX2 and SEPT9 alleles, referred to total
DNA copy numbers. The total DNA copy number was
quantified using a qPCR assay targeting the β-actin
(ACTB) gene locus comprising no CpG sites [15]. A cali-
brator sample (bisulfite-converted artificially methylated
DNA) was used in order to allow for an accurate quanti-
fication as previously described [15].
QM assay
A modified quantitative methylation real-time PCR, called
QM PCR assay [67], was used. It allows a simultaneous
amplification of methylated and unmethylated alleles in a
single tube. The composition of the PCR buffer has been
described earlier [34]. Primers (SHOX2-forward: cctccta
ccttctaaccc, SHOX2-reverse: gttttttggatagttaggtaat, SEPT9-
forward: aaataatcccatccaacta, SEPT9-reverse: gttgtttattagt




taaccacaaaatccaac-BHQ1) were applied in a final
Semaan et al. Clinical Epigenetics  (2016) 8:100 Page 7 of 10
concentration of 0.6 μM each. PCR was performed
with an AB 7500 Fast Real-Time PCR System (Life
Technologies Corporation, Carlsbad, CA, USA) using
the following temperature profile: 15 min at 95 °C of
initial denaturation followed by 45 cycles with 15 s,
95 °C and 60 s, 60 °C. As a calibrator sample for the
QM PCR assay, a 50 % mixture of bisulfite-converted arti-
ficially methylated DNA (CpGenome™ Universal Methyl-
ated DNA; Merck Millipore, Darmstadt, Germany) and
unmethylated DNA (NW Andrology & Cryobank Inc.,
Spokane, WA, USA) was used.
Calculation of methylation levels
The calibrator and all the samples were analyzed in trip-
licate (Triplex assay) and in duplicate (QM assay), re-
spectively. The mean average of the CT values was
calculated and used for further analysis. Previously de-
scribed adapted ΔΔCT methods were applied to deter-
mine a relative methylation value from the QM assay
[68] and the Triplex assay [15] measurements. Invalid
PCR results indicated by high cycle threshold (CT)
values (CTACTB > 33 (Triplex assay); CTmethylated allele >
33 and CTunmethylated allele > 33 (QM assay)) were omitted
from the analysis.
Immunohistochemical staining for MSI
Tumors with MSI are known for their hyper-mutated
genome and epigenetic alternations [4]. To analyze
SHOX2/SEPT9 in association with MSI, immunohisto-
chemical staining (IHC) was used to estimate the protein
expression levels of the four major mismatch repair
enzymes (MLH1, PMS2, MSH2, and MSH6). For this
purpose, tissue microarrays (TMA) were assembled from
formalin-fixed, paraffin-embedded tissue. For each case
(adenoma, carcinoma, control group), representative areas
were marked on the hematoxylin-eosin-stained section.
Subsequently, at least 1-mm cores were punched and
arrayed in a paraffin block. IHC stainings were performed
with a Ventana Benchmark-automated staining system
(Ventana Medical Systems, Tucson, AZ, USA), following
the manufactures’ protocol. The following antibodies from
BD Pharmingen were used: MLH-1 #550838 clon G168-
15 (1:50), MSH-2 #556349 mouse anti-human, MSH6 BD
Pharmingen #610918 mouse anti-human, and PMS2 BD
Pharmingen #556415 mouse monoclonal. The slides were
then counterstained with hematoxylin, dehydrated, and
mounted. Presence of mismatch repair enzymes was then
evaluated by an experienced pathologist.
Availability of data and materials
The TCGA dataset supporting the conclusions of this
article is available in the TCGA data repository (http://
cancergenome.nih.gov/). The dataset supporting the
conclusions of this article is included within the article
and its figures.
Data evaluation and statistical analysis
Values are expressed as mean or median, unless other-
wise stated. Differences between groups were tested
using t test, Mann-Whitney U test, or ANOVA, where
appropriate. Correlation between values was tested using
Spearman’s rank correlation. The Bonferroni correction
was used in case of multiple pairwise comparisons. Re-
ceiver operating characteristic (ROC) curves were calcu-
lated to observe the ability of the methylation level of
SHOX2 and SEPT9 gene loci to differentiate between the
subgroups. Areas under the curve (AUCs) were re-
ported. p values of <0.05 were considered to be statisti-
cally significant. Statistical analyses were performed with
SPSS (IBM, Armonk, NY, USA, version 23) and Graph-
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